Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964362 | 0.90 | CYP19A1 (0.61) | CYP19A1ESR1ESR2CYP1A1CYP1A2 | |
| SCHEMBL2964808 | 0.90 | CYP19A1 (0.60) | CYP19A1ESR1ESR2PTPN1 | |
| SCHEMBL3693283 | 0.89 | ESR1 (0.67) | CYP19A1ESR1ESR2PTPN1POLB | |
| SCHEMBL3693175 | 0.89 | ESR1 (0.67) | CYP19A1ESR1ESR2PTPN1POLB | |
| SCHEMBL2968481 | 0.85 | ESR1 (0.72) | CYP19A1ESR1ESR2PTPN1CYP1A1 | |
| SCHEMBL2970150 | 0.83 | CYP19A1 (0.56) | CYP19A1PTPN1POLBCYP1A1CYP1A2 | |
| SCHEMBL2956557 | 0.83 | CYP19A1 (0.56) | CYP19A1PTPN1POLBCYP1A1CYP1A2 | |
| SCHEMBL22882745 | 0.81 | CYP19A1 (0.62) | CYP19A1ESR1ESR2PTPN1 | |
| SCHEMBL22882748 | 0.81 | FFAR1 (0.49) | CYP19A1ESR1ESR2 | |
| SCHEMBL27975607 | 0.80 | ESR2 (0.76) | CYP19A1ESR1ESR2PTPN1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253226-B1 | Use of hydroxyflavone derivatives for modifying taste | LEIBNIZ INST FÜR PFLANZENBIOCHEMIE IPB (DE) | 2015-07-15 | — | — | EP | claimed |
| EP-2253226-A1 | Use of hydroxyflavone derivatives for modifying taste | Leibniz-Institut für Pflanzenbiochemie (IPB) (DE) | 2010-11-24 | — | — | EP | claimed |
| US-20100292175-A1 | USE OF HYDROXYFLAVAN DERIVATIVES FOR TASTE MODIFICATION | Leibniz-Institut fur Pflanzenbiochemie (DE) | 2010-11-18 | — | — | US | claimed |
| EP-2253226-B1 | Use of hydroxyflavone derivatives for modifying taste | LEIBNIZ INST FÜR PFLANZENBIOCHEMIE IPB (DE) | 2015-07-15 | — | — | EP | disclosed |
| EP-2253226-B1 | Use of hydroxyflavone derivatives for modifying taste | LEIBNIZ INST FÜR PFLANZENBIOCHEMIE IPB (DE) | 2015-07-15 | — | — | EP | disclosed |
| EP-2253226-A1 | Use of hydroxyflavone derivatives for modifying taste | Leibniz-Institut für Pflanzenbiochemie (IPB) (DE) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253226-A1 | Use of hydroxyflavone derivatives for modifying taste | Leibniz-Institut für Pflanzenbiochemie (IPB) (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100292175-A1 | USE OF HYDROXYFLAVAN DERIVATIVES FOR TASTE MODIFICATION | Leibniz-Institut fur Pflanzenbiochemie (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292175-A1 | USE OF HYDROXYFLAVAN DERIVATIVES FOR TASTE MODIFICATION | Leibniz-Institut fur Pflanzenbiochemie (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292175-A1 | USE OF HYDROXYFLAVAN DERIVATIVES FOR TASTE MODIFICATION | Leibniz-Institut fur Pflanzenbiochemie (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-1493431-B1 | Use of an extract of bauhinia for the preparation of pharmaceutical and cosmetic compositions | MERCK PATENT GMBH (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-20080044502-A1 | USE OF AN AQUEOUS OR HYDROALCOHOLIC EXTRACT OF BAUHINIA FOR THE PREPARATION OF A COMPOSITION | WIRTH CORINNA | 2008-02-21 | — | — | US | disclosed |
| US-20060188591-A1 | Bauhinia extracts | BUCHHOLZ HERWIG | 2006-08-24 | — | — | US | disclosed |
| US-20050019426-A1 | For care, protection from aging of skin and hair, use in treatment of various skin disorders such as leukoplakia, eczema, keratosis, psoriasis, or to promote wound healing | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-1493431-A2 | Use of an extract of bauhinia for the preparation of pharmaceutical and cosmetic compositions | MERCK PATENT GmbH (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040170714-A1 | Bauhinia extracts | MERCK PATENT GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1414476-A1 | BAUHINIA EXTRACTS | MERCK PATENT GmbH (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011311-A1 | BAUHINIA EXTRACTS | MERCK PATENT GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019426-A1 | For care, protection from aging of skin and hair, use in treatment of various skin disorders such as leukoplakia, eczema, keratosis, psoriasis, or to promote wound healing | ITCH, CUTA, POLR1C | CYP19A1 1092/4885ESR1 4248/4885ESR2 3519/4885 |
| US-20100292175-A1 | USE OF HYDROXYFLAVAN DERIVATIVES FOR TASTE MODIFICATION | TAS2R50, TAS2R60, TAS2R30 | CYP19A1 3419/4885ESR1 3623/4885ESR2 2632/4885 |
| US-20080044502-A1 | USE OF AN AQUEOUS OR HYDROALCOHOLIC EXTRACT OF BAUHINIA FOR THE PREPARATION OF A COMPOSITION | BROX, HAAO, HIRA | CYP19A1 159/4885ESR1 4614/4885ESR2 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.